pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

6,159 catalysts · 5,539 phase readout · 2,295 8k filing · 379 pdufa · 241 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-03: 0 catalysts2026-08-04: 47 catalysts2026-08-05: 18 catalysts2026-08-06: 12 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 2 catalysts2026-08-11: 1 catalyst2026-08-12: 2 catalysts2026-08-13: 2 catalysts2026-08-14: 1 catalyst2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 1 catalyst2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 0 catalysts2026-10-27: 2 catalysts2026-10-28: 1 catalyst2026-10-29: 3 catalysts2026-10-30: 1 catalyst2026-10-31: 0 catalysts2026-11-01: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: pdufa×type: earnings×type: phase readout×clear all
type
  • phase readout5,539
  • 8k filing2,295
  • pdufa379
  • earnings241
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›ACTIVE_NOT_RECRUITINGphase readoutNCT06652620: Cola Ingestion for Esophageal Bolus Impaction

Sponsor: Fudan University. Phase: NA. Conditions: Esophageal Cancer

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07378982: 3D Printed Ceramic-Filled Photopolymer Resin Vs. CAD/CAM Resin Composite Overlays for Restoration of Extensively Damaged Endodontically Treated Posterior Teeth. An 18-month Follow-up

Sponsor: Cairo University. Phase: NA. Conditions: Endodontically Treated Molar, Dental Restoration, Permanent

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03241420: Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways Disease

Sponsor: National Jewish Health. Phase: . Conditions: Chronic Lung Disease

full page →ctgov ↗
›RECRUITINGphase readoutNCT06047782: Impact of Atrial Fibrosis Surface Area on the Occurrence of Atrial Fibrillation in Patients With Ischemic Stroke of Undetermined Origin: a Prospective Cardiac MRI Pilot Study.

Sponsor: Centre Hospitalier Universitaire Dijon. Phase: NA. Conditions: Stroke, Implantation of an Implantable Cardiac Monitor

full page →ctgov ↗
›RECRUITINGphase readoutNCT07159282: A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers

Sponsor: Applied Biologics, LLC. Phase: PHASE4. Conditions: Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer Due to Type 1 Diabetes Mellitus, Diabetic Foot Ulcer

full page →ctgov ↗
›RECRUITINGphase readoutNCT07650682: Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes

Sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology. Phase: . Conditions: Type 2 Diabetes, Insulin Dependent Diabetes

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07301424: Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

Sponsor: University of Alberta. Phase: PHASE2. Conditions: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia

full page →ctgov ↗
›COMPLETEDphase readoutNCT07434323: Lavender Aromatherapy for Preoperative Anxiety in Melanoma and Epithelioma Patients

Sponsor: San Gallicano Dermatological Institute IRCCS. Phase: NA. Conditions: Melanoma, Non-Melanoma Skin Cancer, Preoperative Anxiety, pT1a

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT05863923: Tobacco Cessation Texting Intervention for People Living With HIV Who Smoke in Vietnam

Sponsor: University of Massachusetts, Worcester. Phase: NA. Conditions: Tobacco Cessation

full page →ctgov ↗
›RECRUITINGphase readoutNCT06485323: MRI Pseudo-CT Sequences for Obstetrical Pelvimetry.

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Phase: NA. Conditions: Obstetric Labor Complications

full page →ctgov ↗
›COMPLETEDphase readoutNCT04095923: A Social Media Game to Increase Physical Activity Among Older Adult Women

Sponsor: The University of Texas Medical Branch, Galveston. Phase: NA. Conditions: Aging

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07515248: Catch up Growth Of Children After Closure Of Hemodinamically Significant Large VSD In Assuit University Children Hospital

Sponsor: Assiut University. Phase: . Conditions: Growth Alteration

full page →ctgov ↗
›SUSPENDEDphase readoutNCT05795855: An Adaptive Prenatal Intervention to Increase Childhood Vaccinations

Sponsor: Emory University. Phase: NA. Conditions: Vaccination Refusal

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07487519: Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

Sponsor: Shanghai Henlius Biotech. Phase: PHASE2. Conditions: Breast Cancer (Triple Negative Breast Cancer (TNBC))

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07632430: End-Tidal CO2 (ETCO2) Trends in Out-of-Hospital Cardiac Arrest

Sponsor: Office of the Medical Director for EMS in Oklahoma City and Tulsa. Phase: . Conditions: Prehospital Resuscitation, End-Tidal Carbon Dioxide, Cardiac Arrest, Out-Of-Hospital, Prehospital Emergency Medical Services

full page →ctgov ↗
›RECRUITINGphase readoutNCT06102330: Multicenter HomeVENT: Home Values and Experiences Navigation Track

Sponsor: Johns Hopkins University. Phase: NA. Conditions: Pediatric ALL, Respiratory Insufficiency, Communication

full page →ctgov ↗
›RECRUITINGphase readoutNCT07273630: Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery

Sponsor: University Hospital, Basel, Switzerland. Phase: NA. Conditions: Hyponatremia, Pituitary Surgery

full page →ctgov ↗
›COMPLETEDphase readoutNCT07590128: Combined Physical Therapy and Hold-Relax Technique for Adolescent Osgood-Schlatter Knee Pain

Sponsor: Benha University. Phase: NA. Conditions: Osgood-Schlatter Disease

full page →ctgov ↗
›RECRUITINGphase readoutNCT07093528: A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

Sponsor: Mayo Clinic. Phase: . Conditions: Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction

full page →ctgov ↗
›COMPLETEDphase readoutNCT04630028: A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Sponsor: Janssen Research & Development, LLC. Phase: PHASE3. Conditions: Colitis, Ulcerative

full page →ctgov ↗
›COMPLETEDphase readoutNCT07538765: Efficacy of TFESI in Lumbar Radicular Pain

Sponsor: Ankara City Hospital Bilkent. Phase: . Conditions: Transforaminal Epidural Steroid Injection, Radicular Low Back Pain

full page →ctgov ↗
›RECRUITINGphase readoutNCT04938765: Effect of Magnesium Sulfate Bolus on Intraoperative Neuromonitoring

Sponsor: Loma Linda University. Phase: PHASE4. Conditions: Intraoperative Neurophysiological Monitoring, Magnesium Sulfate

full page →ctgov ↗
›RECRUITINGphase readoutNCT06578767: Decompression of Pudendal and Inferior Cluneal Nerves Using Robot-assisted Laparoscopy for Entrapment Neuralgias : the X-DECO Study

Sponsor: UBOSGA. Phase: . Conditions: Pudendal Neuralgia

full page →ctgov ↗
›TERMINATEDphase readoutNCT05826600: A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

Sponsor: iOmx Therapeutics AG. Phase: PHASE1. Conditions: Solid Tumor

full page →ctgov ↗
›WITHDRAWNphase readoutNCT06983392: Persistence of Oral DNA Adducts in Smokers and Vapers

Sponsor: University of Minnesota. Phase: NA. Conditions: Smokers, Vaping, Healthy Volunteers

full page →ctgov ↗
›RECRUITINGphase readoutNCT07235592: PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group

Sponsor: Santen SAS. Phase: . Conditions: Primary Open Angle Glaucoma

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06115811: Radiation Treatment Plan Evaluation Learning Tool Pilot Project

Sponsor: Massachusetts General Hospital. Phase: NA. Conditions: Radiation Oncology

full page →ctgov ↗
›RECRUITINGphase readoutNCT07417371: Study on the Mechanism of Pei Tu Ning Feng Tang in Alleviating Tourette Syndrome Via Functional Near-Infrared Spectroscopy (fNIRS) and the DA-MAPK-BDNF Pathway

Sponsor: Dongdong Qin. Phase: NA. Conditions: Tourette Syndrome in Children

full page →ctgov ↗
›COMPLETEDphase readoutNCT06649344: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.. Phase: PHASE3. Conditions: Type 2 Diabetes

full page →ctgov ↗
›COMPLETEDphase readoutNCT05820334: Multiple Sclerosis and Fatigue Assessment

Sponsor: Asli Demirtaş. Phase: . Conditions: Multiple Sclerosis

full page →ctgov ↗
›COMPLETEDphase readoutNCT04146064: Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

Sponsor: University Health Network, Toronto. Phase: . Conditions: NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma, Head and Neck Cancer

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07607899: Virtual Reality for Pain and Well-Being in Older Adults

Sponsor: Laval University. Phase: NA. Conditions: Chronic Pain, Kinesiophobia (Fear of Movement)

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07577999: The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy

Sponsor: Stanford University. Phase: EARLY_PHASE1. Conditions: Non-metastatic Bladder Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT07451899: TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease

Sponsor: Universitas Padjadjaran. Phase: . Conditions: Post Tuberculosis, Lung Disease, Functional Capacity, Spirometry

full page →ctgov ↗
›RECRUITINGphase readoutNCT07214532: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Sponsor: Natera, Inc.. Phase: NA. Conditions: Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)

full page →ctgov ↗
›COMPLETEDphase readoutNCT03508232: Doxycycline to Protect Heart Muscle After Heart Attacks

Sponsor: University of Alberta. Phase: PHASE2. Conditions: ST Segment Elevation Myocardial Infarction, Heart Failure

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07397598: Peer Support for Liver Transplant Recipients With History of ALD

Sponsor: Johns Hopkins University. Phase: NA. Conditions: Alcohol Use Disorder, Alcohol Related Liver Disease, Liver Transplant Recipient

full page →ctgov ↗
›RECRUITINGphase readoutNCT02479698: Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection, Malignant Neoplasm, Merkel Cell Carcinoma, Merkel Cell Polyomavirus Infection, Viral Encephalitis

full page →ctgov ↗
›COMPLETEDphase readoutNCT07527598: Health Web 1.0: A Web-based Occupational Therapy Group Intervention for Older Adults

Sponsor: Luleå Tekniska Universitet. Phase: NA. Conditions: Healthy Older Adults

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07557563: Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma

Sponsor: Chinese University of Hong Kong. Phase: NA. Conditions: Upper Tract Urothelial Carcinoma

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07665398: Effect of Marjoram, Vetiver, and Lavender Oil in the Treatment of Bruxism

Sponsor: Necmettin Erbakan University. Phase: NA. Conditions: Bruxism, Bruxism, Sleep, Bruxism, Sleep-Related

full page →ctgov ↗
›COMPLETEDphase readoutNCT03652493: Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway

Sponsor: Centre Francois Baclesse. Phase: PHASE2. Conditions: Castration-resistant Prostate Cancer, Metastasis

full page →ctgov ↗
›COMPLETEDphase readoutNCT01170793: Medicine Abuse Headache

Sponsor: University Hospital, Bordeaux. Phase: NA. Conditions: Migraine

full page →ctgov ↗
›RECRUITINGphase readoutNCT06099093: Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Sponsor: Brigham and Women's Hospital. Phase: PHASE4. Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07200193: A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B

Sponsor: nChroma Bio. Phase: PHASE1. Conditions: Chronic Hepaititis B

full page →ctgov ↗
›RECRUITINGphase readoutNCT05897021: Expressive Writing on Minority Stressors Among Sexual Minority Veterans

Sponsor: VA Office of Research and Development. Phase: NA. Conditions: Depressive Symptoms, Anxiety

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07501221: Intranasal Dexmedetomidine for Prevention of Intrapartum Fever

Sponsor: Chengdu Jinjiang Maternity and Child Health Hospital. Phase: NA. Conditions: Intrapartum Fever

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07536321: Diagnostic Accuracy and Prognostic Value of 18F FDG PET-CT in the Follow up of Patients With Colorectal Carcinoma.

Sponsor: Assiut University. Phase: . Conditions: Rectal Cancer (Stage III)

full page →ctgov ↗
›RECRUITINGphase readoutNCT07375316: A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

Sponsor: Guangdong Association of Clinical Trials. Phase: PHASE2. Conditions: Non Small Cell Lung Cancer

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06846606: Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc.. Phase: PHASE1. Conditions: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

full page →ctgov ↗
← prev
page 122 of 124
next →